EVEREST MED (01952) plans to acquire all equity of HASTEN BIOPHARMACEUTICALS (SG) PTE. LTD.

Everest Med (01952) announced on April 7, 2026, that the buyer (a wholly-owned subsidiary of Ever Sea Medicines (Singapore) Pte. Ltd.) entered into a share purchase agreement with the seller (Hasten Biopharmaceuticals (Asia) Limited) and the target company (HASTEN BIOPHARMACEUTICALS (SG) PTE. LTD.). Under this agreement, the buyer conditionally agrees to acquire, and the seller conditionally agrees to sell, 100% of the issued share capital of the target company; and the buyer agrees to assume shareholder loans. The target company is a limited company registered in Singapore, primarily engaged in the commercialization of prescription drugs focusing strategically on chronic and critical care areas (especially in the cardiovascular and metabolic sectors). The target company (a wholly-owned subsidiary of the seller) holds asset rights, mainly including rights as the marketing authorization holder for 14 brands of chronic disease products in multiple countries and regions in the Asia-Pacific region, trademarks, and extensive commercial rights. For the financial year ending December 31, 2025, the target company reported normalized revenue of USD 82.232 million and EBITDA of USD 27.273 million. Through the acquisition, the group will gain access to the target company's Asia-Pacific platform and its approximately 120 experienced local sales team members, enabling the group to expand its commercialization capabilities already established and validated in China to the Asia-Pacific region. This will strengthen the group's regional presence, accelerate market entry and execution of existing and future products, and establish the infrastructure and local expertise needed to support future broader international expansion. Furthermore, the expected acquisition will also consolidate the group's business portfolio through the addition of a series of mature brand products with stable demand, expanding the group's revenue base and enhancing the group's business diversification in the Asia-Pacific region. The board of directors believes that the acquisition is strategically important and offers attractive commercial logic: it provides the group with a ready-made regional platform, deepens the group's footprint in relevant therapeutic markets, and strengthens its ability to seize future growth opportunities in the Asia-Pacific region through synergies.